-Reuters
From Benzinga’s Global Small Cap Conference: Brooklyn ImmunoTherapeutics President & CEO, Dr. Howard J. Federoff, M.D., Ph.D. Begins Presenting
https://www.youtube.com/watch?v=B-z-9eznBMU
Related Posts
Eli Lilly Says Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly’s Phase 3 Monotherapy Atopic Dermatitis Trials
New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity
Results suggest less
Bath & Body Works Beats On Q4; Plans Enterprise-Wide Effort To Reduce Expenses
Bath & Body Works Inc (NYSE:BBWI) reported a fourth-quarter FY22 sales decline of 5% year-on-year to $2.89 billion, beating the consensus…
B of A Securities Downgrades Garmin to Neutral, Lowers Price Target to $109
B of A Securities analyst Ronald Epstein downgrades Garmin (NYSE:GRMN) from Buy to Neutral and lowers the price target from $137 to $109.